ENGNW NASDAQ
enGene Holdings Inc. Warrants
1W: +33.0%
1M: -91.2%
3M: -92.8%
YTD: -91.3%
1Y: -68.3%
$0.23
+0.02 (+9.49%)
Weekly Expected Move ±61.1%
$-0
$0
$0
$0
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$11.6M
52W Range0.226-2.1
Volume1,564
Avg Volume13,296
Beta-0.01
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORonald H. W. Cooper
Employees56
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
4868 Rue Levy
Montreal, QC H4S 1Z9
CA
Montreal, QC H4S 1Z9
CA
514 332 4888
About enGene Holdings Inc. Warrants
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CHEUNG ANTHONY TZEYE | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Giguere Lee | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Nichols Alexander Ju | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Daws D. Ryan | A-Award | 220,000 | $9.53 | 2026-01-30 |
| Cooper Ronald Harold | A-Award | 801,000 | $9.53 | 2026-01-30 |